Vismodegib/GDC-0449 was kindly provided by Genentech (San Francisco, US) and LGK-974 was kindly provided by Novartis (Bâle, Switzerland). During vismodegib treatment, mice received 150mg vismodegib/kg mice by oral gavage daily. Vismodegib was administered in two doses (one every 12 hours).
During the 10 day LGK-974 treatment mice received: six days 10mg LGK-974 / kg mice by oral gavage and the last 4 days one topical application of 100 μl of 0.2mg/ml of LGK-974 diluted in propylene glycol: ethanol (7:3 v/v). For oral gavage LGK-974 and vismodegib were dissolved in 0.5% methylcellulose solution containing 0.2% Tween-80.
During the 10 day LGK-974 treatment mice received: six days 10mg LGK-974 / kg mice by oral gavage and the last 4 days one topical application of 100 μl of 0.2mg/ml of LGK-974 diluted in propylene glycol: ethanol (7:3 v/v). For oral gavage LGK-974 and vismodegib were dissolved in 0.5% methylcellulose solution containing 0.2% Tween-80.